copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
An open-label study to determine the maximum tolerated dose of oral ESK . . . ESK-440 uses a novel strategy to target cancers resistant to ALK-targeting drugs by inhibiting both ALK and focal adhesion kinase This first-in-human trial found the maximum tolerated dose of ESK-440 to be 500 mg daily with the most common toxicities to be nausea, vomiting and fatigue
An open-label study to determine the maximum tolerated dose of oral ESK . . . Tyrosine kinase inhibitors (TKIs) targeting ALK have improved disease outcomes, but resistance mechanisms are common This first-in-human trial evaluates ESK-440, a dual inhibitor of ALK and focal adhesion kinase, as a novel strategy for cancers with resistance to ALK-targeting TKIs
ESK-440-靶点: ALK_适应症: 实体瘤-临床_专利_批准 ESK-440是由Michigan Center for Translational Pathology研发的一种小分子药物，是一种ALK抑制剂和FAK抑制剂。 目前该药物最高研发阶段为临床阶段不明，用于治疗实体瘤。
Sol Research Tyrosine kinase inhibitors (TKIs) targeting ALK have improved disease outcomes, but resistance mechanisms are common This first-in-human trial evaluates ESK-440, a dual inhibitor of ALK and focal adhesion kinase, as a novel strategy for cancers with resistance to ALK-targeting TKIs